CLL-18
A Phase 3 Multicentre, Randomised, Prospective, Open-Label Trial Of MRD-Guided Venetoclax/Pirtobrutinib VS. Fixed-Duration, Venetoclax/Pirtobrutinib VS. Fixed Duration, Venetoclax/Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Description: The primary objective of the study is to compare the efficacy of MRD-guided Venetoclax/Pirtobrutinib vs fixed-duration (15 cycles) Venetoclax/Pirtobrutinib
and MRD-guided Venetoclax/Pirtobrutinib vs. fixed-duration (12 cycles) Venetoclax/Obinutuzumab by measuring progression-free survival (PFS) in patients with previously untreated chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL)
Study Phase: Phase 3
Principal Investigator: Dr. Carmel Waldron
Further information